
|Articles|March 3, 2020
Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer
https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
2
AI–Enhanced SALT Score Improves Accuracy in Alopecia Areata Assessment
3
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
4
Behind the Scenes of Multiple Myeloma Care: A Pharmacist’s View With Kelley L. Julian, PharmD, BCOP
5